BioPlus Acquisition Corp.

BioPlus Acquisition Corp. (Nasdaq: BIOS) is a blank check company that completed its IPO in 2021 with a stated focus on the healthcare and life sciences sector, targeting businesses in areas such as biopharmaceuticals, medical technology, and adjacent health-innovation industries. The company filed a Form 10-Q with the SEC on August 14, 2023, under accession number 0001193125-23-212329, reflecting its continued reporting obligations as a registered public entity. As of that filing date, BioPlus remained an active SPAC in the post-IPO search phase, navigating a market environment marked by elevated redemption activity and extended deal timelines across the broader SPAC landscape. Visit SpacDesk and sign up for full data, filings history, and deal-status tracking on BioPlus Acquisition Corp. and hundreds of other active and completed SPACs.